Lakozamid Teva

Lacosamide, the active ingredient in Lakozamid, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy. GNH USA supplies Lakozamid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lakozamid is an anticonvulsant that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces seizure frequency and severity in epilepsy patients. - Epilepsy (adjunct therapy): helps achieve better overall seizure control when added to existing regimens. - Refractory focal epilepsy: provides an additional option for patients not fully controlled by other antiepileptic drugs.

Lakozamid may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Diplopia (double vision) - Somnolence

Serious or Rare Side Effects: - Cardiac arrhythmia (including PR‑interval prolongation) - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior - Elevated liver enzymes or hepatic injury - Blood dyscrasias (e.g., agranulocytosis) - Pancreatitis

When prescribing Lakozamid, clinicians should consider several safety aspects. - Renal impairment: adjust dose according to renal function. - Hepatic impairment: monitor liver function tests regularly. - Concomitant antiepileptic drugs: assess for potential pharmacokinetic interactions. - Pregnancy: use only if the potential benefit outweighs the risk to the fetus. - Driving or operating machinery: caution due to possible dizziness or somnolence. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lakozamid can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: may significantly lower lacosamide plasma concentrations. - Phenytoin: can reduce the therapeutic effect of lacosamide. - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide exposure.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression. - Other sodium‑channel blockers (e.g., lamotrigine): additive effect on seizure control and side‑effects. - Hormonal contraceptives: possible reduction in contraceptive efficacy.